Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-08-13
2010-06-29
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C548S517000, C548S526000, C548S562000, C548S563000
Reexamination Certificate
active
07745481
ABSTRACT:
Certain cyclooxygenase-2 inhibitors are useful for the treatment and prevention of tumors and tumor-related disorders and cachexia.
REFERENCES:
patent: 4962119 (1990-10-01), Boschelli et al.
patent: 5208018 (1993-05-01), Gough
patent: 5317019 (1994-05-01), Bender et al.
patent: 5344991 (1994-09-01), Reitz et al.
patent: 5380738 (1995-01-01), Norman et al.
patent: 5418254 (1995-05-01), Huang et al.
patent: 5466823 (1995-11-01), Talley et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5486534 (1996-01-01), Lee et al.
patent: 5521207 (1996-05-01), Graneto
patent: 5550142 (1996-08-01), Ducharme et al.
patent: 5593991 (1997-01-01), Adams et al.
patent: 5616601 (1997-04-01), Khanna et al.
patent: 5620999 (1997-04-01), Weier et al.
patent: 5633272 (1997-05-01), Talley et al.
patent: 5908858 (1999-06-01), Kimura et al.
patent: 5932598 (1999-08-01), Talley et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 6469040 (2002-10-01), Seibert et al.
patent: 2180624 (1997-01-01), None
patent: 0 745 596 (1996-12-01), None
patent: 0 688 723 (1997-10-01), None
patent: 0 799 823 (1997-10-01), None
patent: 0 863 134 (1998-09-01), None
patent: WO 92/10190 (1992-06-01), None
patent: WO 92/10498 (1992-06-01), None
patent: WO 94/13635 (1994-06-01), None
patent: WO 94/15932 (1994-07-01), None
patent: WO 94/27980 (1994-12-01), None
patent: WO 95/00501 (1995-01-01), None
patent: WO 95/02600 (1995-01-01), None
patent: WO 95/11883 (1995-05-01), None
patent: WO 95/15316 (1995-06-01), None
patent: WO 95/18799 (1995-07-01), None
patent: WO 95/30656 (1995-11-01), None
patent: WO 95/32194 (1995-11-01), None
patent: WO 96/03385 (1996-02-01), None
patent: WO 96/03387 (1996-02-01), None
patent: WO 96/03388 (1996-02-01), None
patent: WO 96/25405 (1996-08-01), None
patent: WO 96/36617 (1996-11-01), None
patent: WO 96/38418 (1996-12-01), None
patent: WO 97/13755 (1997-04-01), None
patent: WO 97/27181 (1997-07-01), None
patent: WO 97/38986 (1997-10-01), None
patent: WO 98/06708 (1998-02-01), None
patent: WO 98/16227 (1998-04-01), None
patent: WO 98/22101 (1998-05-01), None
patent: WO 98/25896 (1998-06-01), None
J.J. Li et al., “1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-Inflammatory Agents”,Journal of Medicinal Chemistry, vol. 38, No. 22, pp. 4570-4578, Oct. 1995.
N. Futaki et al., NS-398, “A New Anti-Inflammatory Agent, Selectively Inhibits Prostaglandin G/H Synthase/Cyclooxygenase (COX-2) Activity In Vitro”,Prostaglandins, vol. 47, pp. 55-59, Jan. 1994.
K. Tanaka et al., T-614, “A Novel Antirheumatic Drag, Inhibits Both the Activity and Induction of Cyclooxygenase-2 in Cultured Fibroblasts”,Japanese Journal of Pharmacology, vol. 67, No. 4, pp. 305-314, Apr. 1995.
X. Lu et al, “NSAID-Induced Apoptosis in Rous Sarcoma Virus-Transformed Chicken Embryo Fibroblasts is Dependent on v-src and c-myc and is Inhibited by bcl-2”,Prostaglandins, vol. 54, pp. 549-568 (Aug. 1997).
T. Hla et al, “Role of the Early Response Gene Cyclooxygenase (COX) -2 in Angiogenesis”,Molecular, Cellular, and Clinical Aspects of Angiogenesis, Edited by M.E. Maragoudakis, Plenum Press, Nato ASI Series, Series A: Life Series, vol. 285, pp. 191-198 (1996).
N. Yoshimi et al, “Inhibitory Effect of NS-398, a Selective Cyclooxygenase-2 Inhibitor, on Azoxymethane-induced Aberrant Crypt Foci in Colon Carcinogenesis of F344 Rats”,Jpn. J. Cancer Res., vol. 88, pp. 1044-1051 (Nov. 1997).
N. Rioux et al, “Recovery from 4-(MethylInitrosamino)-1-(3-pyridyl)-1-butanone-Induced Immunosuppression in A/J Mice by Treatment With Nonsteroidal Anti-inflammatory Drugs”,J. Natl. Cancer Inst., vol. 89, No. 12, pp. 874-880 (Jun. 1997).
K.K. Wu, “Cyclooxygenase 2 Induction: Molecular mechanism and pathophysiologic roles”,J. Lab. Clin. Med., vol. 128, No. 3, pp. 242-245 (1996).
H. Sheng et al, “Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2”,J. Clin. Invest., vol. 99, No. 9, pp. 2254-2259 (May 1997).
M. Takahashi et al, “Suppression of azoxymethane-induced aberrant crypt focl in rat colon by nimesulide, a selective Inhibitor of cyclooxygenase 2”,J. Cancer Res. Clin. Oncol., vol. 122, pp. 219-222 (1996).
M.L. Parrett et al, “Cyclooxygenase-2 gene expression in human breast cancer”,Int. J. Oncol., vol. 10, pp. 503-507 (1997).
H.A. Lehmann et al, “Meloxicam: A Toxicology Overview”,Inflammopharmacology, vol. 4, pp. 105-123, Klumer Academic Publishers (1996).
M. Katori, “Solid tumor, plasma exudation arachidonic acid metabolism”,Igaku no Ayumi, vol. 175, No. 8, pp. 527-531 (1995).
G.G. Sheng et al, “A Selective Cyclooxygenase 2 Inhibitor Suppresses the Growth of H-ras-Transformed Rat Intestinal Epithelial Cells”,Gastroenterology, vol. 113, No. 6, pp. 1883-1891 (Dec. 1997).
P. Huang et al, “Cyclooxygenase and 5-lipoxygenase inhibitors for the prevention and treatment of cancer”, Oncologic, Endocrine & Metabolic—Monthly Update,Exp. Opin. Invest. Drugs, vol. 4, No. 3, pp. 243-249 (1995).
D.J.E. Elder et al, “Induction of Apoptotic Cell Death in Human Colorectal Carcinoma Cell Lines by a Cyclooxygenase-2 (COX)-2)- selective Nonsteroidal Anti-Inflammatory Drug: Independence from COX-2 Protein Expression”,Clin. Cancer Res., vol. 3, pp. 1679-1683 (Oct. 1997).
M. Tsujii et al, “COX-2 . . . ”,Chiryougaku, vol. 30, No. 12, pp. 1401-1405 (1996).
M. Tsujii et al, Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase 2,Cell, vol. 83, pp. 493-501 (1995).
D. DeWitt et al, “Yes, but Do They Still Get Headaches?”,Cell, vol. 83, pp. 345-348 (1995).
P.K. Lala et al, “Effects of Chronic Indomethacin Therapy on the Development and Progression of Spontaneous Mammary Tumors in C3H/HEJ Mice”,Int. J. Cancer, vol. 73, pp. 371-380 (1997).
B.S. Reddy et al, “Evaluation of Cyclooxygenase-2 Inhibitor for Potential Chemopreventive Properties in Colon Carcinogenesis”,Cancer Res., vol. 56, pp. 4566-4569 (1996).
I.K. Khanna et al, “1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents”,J. Med. Chem., vol. 40, pp. 1634-1647 (1997).
I.K. Khanna et al, “1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2”,J. Med. Chem., vol. 40, pp. 1619-1633, (1997).
Oshima, et al., “Suppression of Intestinal Polyposis inApcΔ716Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)”,Cell, vol. 87, pp. 803-809, Nov. 29, 1996.
Teicher, et al., “Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies”,Cancer Chemother Pharmacol, vol. 33, pp. 515-522, (1994).
Tsujii M. et al., “Cycoloxygenase-2 expression in human colon cancer cells increases metastatic potential”, Proc. Natl. Acad. Sci. USA 1997, Apr. 1; 94 (7), B9533, 36-40, Abstract, Medline (on-line) Department of Medicine USA, No. 97250538.
Ristimakia et al., Expression of cyclooxygenase-2 in human gastric carcinoma, Cancer, Res., Apr. 1, 1997; 57(7), 1276-80, Abstract, Medline (on-line) Department of Medicine USA.
McCarthy, “Inhibitors of Prostaglandin Synthesis Do Not Improve Food Intake or Body Weight of Tumor-Bearing Rats”,Research in Nursing&Health, 1999, pp. 380-387, vol. 22).
Breuille, et al., “A Sustained Rat Model for Studying the Long- Lasting Catabolic State of Sepsis”;Infection and Immunity, Mar. 1999, pp. 1079-1085, vol. 67, No. 3.
Mori et al, “Purification of a Lipoprotein Lipase-Inhibiting Protein Produced by a Melanoma Cell Line Associated With Cancer Cachexia”,Biochemical and Biophysical Research Communications, May 15, 1989, pp. 1085-1092, vol. 160, No. 3.
Strassmann et al., “Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy”,Cytokines and M
Hanai Masaharu
Kanai Saori
Kimura Tomio
Kurakata Shinichi
Daiichi Sankyo Company, Limited
Frishauf Holtz Goodman & Chick P.C.
Lewis Patrick T
LandOfFree
Methods and compositions for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151895